Last reviewed · How we verify
NCT07141004
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
Phase 4 trial testing Guselkumab in Arthritis, Psoriatic in 100 participants. Currently enrolling.
5 June 2027
Quick facts
| Lead sponsor | Johnson & Johnson Private Limited |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 12 August 2025 |
| Primary completion | 5 June 2027 |
| Estimated completion | 11 September 2027 |
| Sites | 9 locations across India |
Drugs / interventions tested
- Guselkumab (GUSELKUMAB) — full drug profile →
Conditions studied
- Arthritis, Psoriatic — all drugs for Arthritis, Psoriatic →
Sponsor
Johnson & Johnson Private Limited — full company profile →
Who can join
18 and older, any sex, with Arthritis, Psoriatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07141004
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Guselkumab
Trials testing the same drug.
- NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
- NCT07528040 — An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With C · not yet recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT06916390 — GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis · Phase 4 · not yet recruiting
- NCT06586281 — Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy · NA · recruiting
Other recruiting trials for Arthritis, Psoriatic
Currently open trials in the same condition.
- NCT07321873 — A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arth · Phase 2 · recruiting
- NCT07220824 — A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting · recruiting
- NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
- NCT06878404 — A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Pso · Phase 3 · active not recruiting
- NCT06807424 — A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Acti · Phase 3 · recruiting
Other Johnson & Johnson Private Limited trials
Trials by the same sponsor.
- NCT07030517 — A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma · Phase 4 · recruiting
- NCT04288778 — A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exer · Phase 4 · completed
- NCT03190330 — A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma · Phase 4 · completed
- NCT03768960 — A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Ther · Phase 4 · completed
- NCT03733925 — A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis o · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07141004 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johnson & Johnson Private Limited
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07141004.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing